Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 DiabetesRury R. Holman, Adrian F. Hernandez, M. Angelyn Bethel et al.|New England Journal of Medicine|2017Cited by 2.1k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trialAdrian F. Hernandez, Lauren B. Cooper, Jennifer B. Green et al.|The Lancet|2018Cited by 1.8k
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysisKazem Rahimi, Takayoshi Ohkubo, Barry R. Davis et al.|The Lancet|2021Cited by 997
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysisM. Angelyn Bethel, Rury R. Holman, Rishi Patel et al.|The Lancet Diabetes & Endocrinology|2017Cited by 591
Recommendations for Biomarker Identification and Qualification in Clinical ProteomicsHarald Mischak, Antonia Vlahou, Günter Allmaier et al.|Science Translational Medicine|2010Cited by 335